What if we could prevent treatable disease before it developed?
That’s precisely our goal.
We are ICoNS
The International Consortium on Newborn Sequencing
ICoNS is an alliance of genomic scientists and stakeholders who share a vision of responsibly implementing newborn sequencing to predict treatable disease in babies and intervene before symptoms begin.
Our mission is to inform the clinical and public health research and implementation of genomic screening in newborns through the harmonization and aggregation of scientific evidence and resources.
We do this by promoting the exchange of ideas and encouraging an open forum for leaders in this space, establishing a common vision for newborn sequencing as a public health tool, and organizing efforts needed to advance the field.
Newborn Sequencing
A Brief Synopsis
-
Results from genome sequencing at birth can detect risk for treatable disease before symptoms even start, allowing clinicians to manage or prevent the onset of disease.
-
Newborn sequencing is far more comprehensive than current newborn screening and can be referred to throughout the lifespan, allowing individuals to make proactive healthcare decisions that may improve their future and the health of their family.
-
Integrating newborn sequencing into everyday medicine will require careful consideration for healthcare systems and for families, including strategies that address privacy issues, cost, equity, clinician education, and more.
Newborn sequencing has long been viewed as the future of preventive medicine, offering parents early guidance on care that is tailored to their child.
The future starts now.
